Alnylam Pharmaceuticals Change in Other Assets decreased by 91.1% to $6.32M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 80.7%, from $32.77M to $6.32M.
Large swings are usually related to the timing of prepayments for services or long-term supply agreements.
This captures the net change in miscellaneous operating assets not classified as receivables or inventory, such as prepa...
This is typically a smaller component of cash flow for most large-cap technology firms unless they are securing long-term supply capacity.
change_in_other_assets| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.97M | $18.14M | $29.85M | $21.31M | -$3.97M | $1.24M | $27.87M | $3.32M | $75.46M | -$61.69M | $8.28M | -$25.28M | $32.77M | -$6.78M | $20.74M | $70.99M | $6.32M |
| QoQ Change | — | +6.9% | +64.5% | -28.6% | -118.6% | +131.1% | >999% | -88.1% | >999% | -181.7% | +113.4% | -405.4% | +229.6% | -120.7% | +406.1% | +242.3% | -91.1% |
| YoY Change | — | — | — | +25.6% | -121.9% | -95.9% | +30.8% | +183.7% | >999% | -321.3% | +149.5% | — | -56.6% | +89.0% | +150.6% | +380.8% | -80.7% |